Andrew Berens
Stock Analyst at Leerink Partners
(1.27)
# 3,618
Out of 4,981 analysts
95
Total ratings
46.43%
Success rate
-10.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $54.91 | +9.27% | 2 | Jul 28, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $16 → $18 | $12.66 | +42.18% | 5 | Jul 7, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $125 → $140 | $80.54 | +73.83% | 2 | Jun 24, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $7.74 | +16.28% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $3.57 | +68.07% | 3 | Apr 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Market Perform | $880 → $762 | $560.00 | +36.07% | 1 | Jan 28, 2025 | |
| OKUR OnKure Therapeutics | Initiates: Outperform | $33 | $2.45 | +1,246.94% | 1 | Dec 5, 2024 | |
| ZYME Zymeworks | Upgrades: Outperform | $10 → $25 | $15.73 | +58.93% | 10 | Nov 7, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $74 → $96 | $114.55 | -16.19% | 1 | Oct 21, 2024 | |
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $36.77 | +52.30% | 11 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $83.10 | -6.14% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $69.53 | -30.97% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $9.05 | +209.39% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $79.56 | -0.70% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.49 | +1,712.08% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $6.53 | +282.85% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.18 | +547.25% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.66 | +2,418.80% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $4.81 | +315.80% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $6.53 | +282.85% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $12.81 | -37.55% | 7 | Jul 14, 2017 |
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $54.91
Upside: +9.27%
Cogent Biosciences
Jul 7, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $12.66
Upside: +42.18%
Nuvalent
Jun 24, 2025
Maintains: Outperform
Price Target: $125 → $140
Current: $80.54
Upside: +73.83%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $7.74
Upside: +16.28%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $3.57
Upside: +68.07%
Regeneron Pharmaceuticals
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $560.00
Upside: +36.07%
OnKure Therapeutics
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.45
Upside: +1,246.94%
Zymeworks
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $15.73
Upside: +58.93%
Gilead Sciences
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $114.55
Upside: -16.19%
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $36.77
Upside: +52.30%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $83.10
Upside: -6.14%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $69.53
Upside: -30.97%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $9.05
Upside: +209.39%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $79.56
Upside: -0.70%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.49
Upside: +1,712.08%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $6.53
Upside: +282.85%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $6.18
Upside: +547.25%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.66
Upside: +2,418.80%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $4.81
Upside: +315.80%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $6.53
Upside: +282.85%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $12.81
Upside: -37.55%